GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Feedback PLC (LSE:FDBK) » Definitions » COGS-to-Revenue

Feedback (LSE:FDBK) COGS-to-Revenue : 0.08 (As of Nov. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Feedback COGS-to-Revenue?

Feedback's Cost of Goods Sold for the six months ended in Nov. 2023 was £0.04 Mil. Its Revenue for the six months ended in Nov. 2023 was £0.44 Mil.

Feedback's COGS to Revenue for the six months ended in Nov. 2023 was 0.08.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Feedback's Gross Margin % for the six months ended in Nov. 2023 was 91.76%.


Feedback COGS-to-Revenue Historical Data

The historical data trend for Feedback's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Feedback COGS-to-Revenue Chart

Feedback Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 - 0.09 0.17 0.08

Feedback Semi-Annual Data
May14 Nov14 May15 Nov15 May16 Nov16 May17 Nov17 May18 Nov18 May19 Nov19 May20 Nov20 May21 Nov21 May22 Nov22 May23 Nov23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.10 0.06 0.10 0.08

Feedback COGS-to-Revenue Calculation

Feedback's COGS to Revenue for the fiscal year that ended in May. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.084 / 1.025
=0.08

Feedback's COGS to Revenue for the quarter that ended in Nov. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.036 / 0.437
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Feedback  (LSE:FDBK) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Feedback's Gross Margin % for the six months ended in Nov. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.036 / 0.437
=91.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Feedback COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Feedback's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Feedback (LSE:FDBK) Business Description

Traded in Other Exchanges
N/A
Address
3-7 Temple Avenue, 201 Temple Chambers, London, GBR, EC4Y 0DT
Feedback PLC is a medical imaging software and tools company. It develops and markets imaging tools and software for clinical decision-making and also techniques and improved workflow for medical practitioners engaged in research and in treating patients. The company also entered into a joint venture for future clinical application of its products on patients with kidney stones and it has a medical imaging segment.

Feedback (LSE:FDBK) Headlines

No Headlines